In case of early BC, the assessment of therapeutic targets is so far restricted to the primary tumor despite increasing evidence of significant discordances between primary tumor and MRD, especially with respect to hormone receptor and HER2 status. This evidence concerns the gene NR4A1 and breast cancer.